New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
08:01 EDTRHHBY, HALOHalozyme announces Roche marketing authorization for MabThera SC
Halozyme (HALO) announced that the European Commission has approved Roche's (RHHBY) new subcutaneous formulation of MabThera for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. Following the approval of Herceptin SC in September 2013, this is the second European approval for a novel subcutaneous formulation of one of Roche's oncology products using Halozyme's patented Enhanze technology. The European approval was primarily based on data from the pivotal SABRINA study, which was recently published in the Lancet Oncology. Roche has stated that they expect to begin launching MabThera SC in a number of European markets throughout 2014.
News For HALO;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
08:03 EDTRHHBYPTC to receive $10M milestone payment from Roche as SMA program advances
Subscribe for More Information
07:52 EDTRHHBYInforma Business Information to hold a conference
Subscribe for More Information
November 18, 2014
14:59 EDTRHHBYRanbaxy sues FDA for rescinding approval of Nexium, Valcyte copies, Reuters says
Subscribe for More Information
11:22 EDTRHHBYTeva patent victory over Warner Chilcott, Roche affirmed
The U.S. Court of Appeals for the Federal Circuit ruled that a district court was correct to grant summary judgment to Teva (TEVA) in a patent dispute with Warner Chilcott and Roche (RHHBY) over patents related to osteoporosis drug risedronate.
November 17, 2014
05:30 EDTRHHBYInovio, Roche terminate collaboration for INO-5150
Subscribe for More Information
November 14, 2014
14:53 EDTRHHBYCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
13:27 EDTRHHBYRoche reports FDA nod for Avastin in platinum-resistant recurrent ovarian cancer
Subscribe for More Information
November 12, 2014
11:17 EDTRHHBYLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
07:22 EDTRHHBYAssociation of Molecular Pathology is holding annual meeting
2014 Annual Meeting of AMP is being held in National Harbor, Maryland on November 12-15.
November 11, 2014
15:43 EDTRHHBYLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
09:18 EDTHALOHalozyme price target lowered to $10 from $12 at JMP Securities
JMP Securities cut its price target on Halozyme after the company said it intends to explore partnerships and/or strategic alternatives for the Hylenex program in diabetes. The firm removed the diabetes program from its valuation due to uncertainty. It reiterates an Outperform rating on the shares.
November 10, 2014
18:32 EDTHALOOn The Fly: After Hours Movers
Subscribe for More Information
17:26 EDTHALOHalozyme completes workforce reduction
The company noted, "We completed a corporate reorganization to align with strategic priorities. This reorganization resulted in a workforce reduction of 22 employees. We will incur a one-time charge in Q414 that will be largely offset by reduced compensation expenses during the quarter."
16:19 EDTHALOHalozyme reports Q3 EPS (16c), consensus (14c)
Subscribe for More Information
16:07 EDTRHHBYUBS to hold a conference
UBS European Conference is being held in London, England on November 11-12.
15:26 EDTHALONotable companies reporting after market close
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use